As per our report, the size of the Latin America Generic drugs market has been calculated at USD 37.14 billion in 2022. It is expected to reach USD 50.67 billion by 2027, growing at a CAGR of 6.41% from 2022 to 2027.
The pharmaceutical industry plays a vital role in the growth of generic drugs. The primary drivers of the Latin American generic drugs market are patent expiration it helps initial developer produce lower-cost generic variants and introduce into the market. Generic drugs are of same quality there may some changes in flavor, size, and color but it acts same as the branded drugs. Dosing, safety, strength, quality, how it operates, how it is taken, and how it should be utilized are all the same as the branded drugs.
People prefer most generic drugs as they are cost-efficient and affordable. In addition, an increase in the rates of rising chronic illness is boosting the sales of generic, advances in the formulation of the drugs, and market players are also driving the market growth.
However, patient preferences and assumptions are less likely to choose generic drugs because they believe generic therapies are inferior to branded treatments. Doctors rarely prescribe generic drugs, and chemists only supply medicines that are written on the prescription. In addition, the FDA’s strict guidelines and rules for the approval, side effects of the drugs due to some variation during formulation, color, or flavor are restraining the market growth. Doctor preference towards brands and their brand loyalty towards the branded drugs. Also, generic drugs are not possible as it takes a long time to expire any patent.
This research report on the Latin America generic drugs market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Country:
Based on region, Brazil has the highest CAGR in this region. On the other hand, Mexico is estimated to experience strong growth in the generic drug market in the coming future. Also, it is expected to increase the demand with supportive industry and government initiatives; the market is expected to expand the growth of generic medicine during the forecast period.
KEY MARKET PLAYERS:
Companies playing a noteworthy role in the Latin America generic drugs market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Biosimilars
5.1.3 simple generics
5.1.4 Super generics
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Therapeutic drugs
5.2.1 Introduction
5.2.2 Cardiovascular Products
5.2.3 Anti-infective Drugs
5.2.4 Anti Arthritis Drugs
5.2.5 Central Nervous System Drugs
5.2.6 Anti Cancer Drugs
5.2.7 Respiratory System Drugs
5.2.8 Others
5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs
5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs
5.2.11 Market Share Analysis, By Therapeutic Drugs
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Therapeutic Drugs
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Therapeutic Drugs
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By type
6.1.5.3 By Therapeutic Drugs
6.2 Brazil
6.3 Argentina
6.4 Mexico
6.5 Chile
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Ranbaxy Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Actavis
8.3 Mylan, Inc. Industries, Ltd.
8.4 Dr. Reddy’s Laboratories
8.5 Par Pharmaceutical, Inc.
8.6 Sandoz International GmbH
8.7 Celgene Corporation
8.8 Apotex, Inc.
8.9 Watson Pharmaceuticals, Ltd.
8.10 Teva Pharmaceutical and others.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
